Anagrelide vs. Hydroxyurea in Essential Thrombocythemia: Efficacy Profiles and Clinical Positioning

　　In the cytoreductive management of essential thrombocythemia(ET),anagrelide(Anagrelide)and hydroxyurea(Hydroxyurea)are two widely utilized therapeutic agents.Both effectively reduce platelet counts;however,they differ significantly in mechanism of action,prevention of vascular events,adverse effect profiles,and long-term therapeutic positioning.It would be an oversimplification to declare one universally superior to the other.In clinical practice,treatment selection should be guided by individual risk stratification,comorbidities,and patient-specific tolerability.

　　Regarding their mechanisms of action,anagrelide primarily interferes with megakaryocyte maturation,thereby selectively suppressing platelet production with minimal impact on other hematopoietic lineages.Hydroxyurea,by contrast,is a broad-spectrum cytoreductive agent that inhibits ribonucleotide reductase and disrupts DNA synthesis,affecting multiple cell lines including white blood cells,red blood cells,and platelets.Multiple overseas randomized controlled trials have demonstrated that both agents effectively control platelet counts,with some studies suggesting that anagrelide is non-inferior to hydroxyurea in platelet reduction.

　　In terms of comprehensive vascular event control,landmark randomized trials in high-risk ET patients have shown that hydroxyurea combined with low-dose aspirin outperforms anagrelide combined with low-dose aspirin in reducing composite vascular events,including arterial thrombosis,venous thrombosis,and major hemorrhage.Subsequent meta-analyses have reinforced these findings,indicating that hydroxyurea offers a modest advantage in reducing major bleeding and composite vascular endpoints,while anagrelide provides acceptable thrombotic event prevention but relatively weaker hemorrhage control.

　　The adverse effect profiles of the two agents differ considerably.Common side effects of anagrelide include headache,palpitations,tachycardia,and gastrointestinal discomfort,largely attributable to its phosphodiesterase inhibitory activity.Some patients may require dose adjustment or discontinuation due to cardiovascular intolerance.Hydroxyurea,owing to its broader myelosuppressive effects,may cause leukopenia,anemia,and other hematologic changes.Long-term users may also need monitoring for cutaneous ulcers,mucosal changes,and other chronic tolerability issues.Given these distinct safety profiles,thorough baseline assessment is essential before selecting either agent.

　　In clinical treatment positioning,hydroxyurea and pegylated interferon are generally regarded as first-line cytoreductive options for high-risk ET patients,supported by mature long-term evidence.Anagrelide is more commonly reserved as an alternative for patients who are intolerant of,refractory to,or have contraindications to hydroxyurea.International treatment guidelines as of 2024 continue to designate hydroxyurea and pegylated interferon as primary first-line therapies.This does not imply that anagrelide is therapeutically inferior;rather,it reflects objective differences in long-term safety data,mechanism of action,and target patient populations between the two agents.

　　In summary,both anagrelide and hydroxyurea are effective in lowering platelet counts,yet their therapeutic roles do not fully overlap.Hydroxyurea benefits from more extensive long-term clinical evidence in high-risk ET and holds an advantage in composite thrombotic and hemorrhagic risk management.Anagrelide,with its selective inhibition of platelet production,offers irreplaceable value for patients who cannot tolerate or are unsuitable for hydroxyurea.Current evidence also confirms that anagrelide is not simply"less effective than hydroxyurea";the principal distinctions between the two lie in long-term risk characteristics,drug tolerability,and specific clinical scenarios.Individualized assessment and precision prescribing remain the cornerstone of cytoreductive therapy in ET.